Abstract
Background: Nasal congestion is the predominant symptom in perennial allergic rhinitis (PAR), and it seems to be mainly related to the late-phase inflammatory events. The present pilot study aimed to evaluate the therapeutic effect exerted by fexofenadine in patients with PAR due to mite allergy. Methods: This study was a parallel, double-blind, randomized, three-arm (1:1:1), placebo-controlled study. Thirty-one subjects with PAR were enrolled and received double-blind medication: fexofenadine 120 or 180 mg, or placebo, once a day for 28 days. Results: The total symptom score was reduced by fexofenadine (both dosages) at V2 (P = 0.007), whereas placebo did not modify it. Nasal congestion decreased after 1 week of treatment with fexofenadine 120 (P = 0.027) and 180 (P = 0.01), but not with placebo (P = NS). At V3, fexofenadine (both dosages) significantly reduced nasal congestion (P = 0.011 and P = 0.007, respectively), by placebo did not show any significant effect. Conclusions: This pilot study represents the first evidence of the efficacy of fexofenadine in PAR, and also the control of the nasal congestion. We suggest performing larger trials to confirm these preliminary findings.
| Original language | English |
|---|---|
| Pages (from-to) | 1068-1070 |
| Number of pages | 3 |
| Journal | Allergy: European Journal of Allergy and Clinical Immunology |
| Volume | 56 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2001 |
Fingerprint
Keywords
- Fexofenadine
- Perennial allergic rhinitis
ASJC Scopus subject areas
- Immunology
Cite this
Fexofenadine reduces nasal congestion in perennial allergic rhinitis. / Ciprandi, G.; Cosentino, C.; Milanese, M.; Mondino, C.; Canonica, G. W.
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 56, No. 11, 2001, p. 1068-1070.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fexofenadine reduces nasal congestion in perennial allergic rhinitis
AU - Ciprandi, G.
AU - Cosentino, C.
AU - Milanese, M.
AU - Mondino, C.
AU - Canonica, G. W.
PY - 2001
Y1 - 2001
N2 - Background: Nasal congestion is the predominant symptom in perennial allergic rhinitis (PAR), and it seems to be mainly related to the late-phase inflammatory events. The present pilot study aimed to evaluate the therapeutic effect exerted by fexofenadine in patients with PAR due to mite allergy. Methods: This study was a parallel, double-blind, randomized, three-arm (1:1:1), placebo-controlled study. Thirty-one subjects with PAR were enrolled and received double-blind medication: fexofenadine 120 or 180 mg, or placebo, once a day for 28 days. Results: The total symptom score was reduced by fexofenadine (both dosages) at V2 (P = 0.007), whereas placebo did not modify it. Nasal congestion decreased after 1 week of treatment with fexofenadine 120 (P = 0.027) and 180 (P = 0.01), but not with placebo (P = NS). At V3, fexofenadine (both dosages) significantly reduced nasal congestion (P = 0.011 and P = 0.007, respectively), by placebo did not show any significant effect. Conclusions: This pilot study represents the first evidence of the efficacy of fexofenadine in PAR, and also the control of the nasal congestion. We suggest performing larger trials to confirm these preliminary findings.
AB - Background: Nasal congestion is the predominant symptom in perennial allergic rhinitis (PAR), and it seems to be mainly related to the late-phase inflammatory events. The present pilot study aimed to evaluate the therapeutic effect exerted by fexofenadine in patients with PAR due to mite allergy. Methods: This study was a parallel, double-blind, randomized, three-arm (1:1:1), placebo-controlled study. Thirty-one subjects with PAR were enrolled and received double-blind medication: fexofenadine 120 or 180 mg, or placebo, once a day for 28 days. Results: The total symptom score was reduced by fexofenadine (both dosages) at V2 (P = 0.007), whereas placebo did not modify it. Nasal congestion decreased after 1 week of treatment with fexofenadine 120 (P = 0.027) and 180 (P = 0.01), but not with placebo (P = NS). At V3, fexofenadine (both dosages) significantly reduced nasal congestion (P = 0.011 and P = 0.007, respectively), by placebo did not show any significant effect. Conclusions: This pilot study represents the first evidence of the efficacy of fexofenadine in PAR, and also the control of the nasal congestion. We suggest performing larger trials to confirm these preliminary findings.
KW - Fexofenadine
KW - Perennial allergic rhinitis
UR - http://www.scopus.com/inward/record.url?scp=0034751569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034751569&partnerID=8YFLogxK
U2 - 10.1034/j.1398-9995.2001.00191.x
DO - 10.1034/j.1398-9995.2001.00191.x
M3 - Article
C2 - 11703220
AN - SCOPUS:0034751569
VL - 56
SP - 1068
EP - 1070
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0105-4538
IS - 11
ER -